38 patents
Utility
Cyclic polypeptides for PCSK9 inhibition
14 Nov 23
Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds.
Alonso Ricardo, Nicolas Cedric Boyer, Joseph R. Stringer, Derek M. LaPlaca, Ketki Ashok Dhamnaskar, Zhong Ma, Jonathan C. Blain, Rohit Vyasamneni
Filed: 20 Jun 19
Utility
Cyclic polypeptides for PCSK9 inhibition
14 Nov 23
Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds.
Alonso Ricardo, Nicolas Cedric Boyer, Joseph R. Stringer, Derek M. LaPlaca, Kelli Jette, Yili Sun
Filed: 20 Jun 19
Utility
Cyclic Polypeptides for PCSK9 Inhibition
28 Sep 23
Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds.
Alonso Ricardo, Thomas Joseph Tucker, Nicolas Cedric Boyer, Joseph R. Stringer, Derek M. LaPlaca, Angela Dawn Kerekes, Chengwei Wu, Sookhee Nicole HA, Hyewon Youm, Mark W. EMBREY, Elisabetta Bianchi, Danila Branca, Raffaele Ingenito, Willy Costantini, Alessia Santoprete, Roberto Costante, Immacolata Conte, Stefania Colarusso, Eric J. GILBERT, Aurash Shahripour, Yusheng Xiong
Filed: 27 Sep 22
Utility
Modulators of complement activity
12 Sep 23
The present invention relates to polypeptide modulators of complement activity, including cyclic polypeptide modulators.
Steven James DeMarco, Michelle Denise Hoarty, Grace Victoria Parker, Alonso Ricardo, Sylvia Tobe, Douglas A. Treco
Filed: 8 Oct 20
Utility
Modulators of complement activity
15 Aug 23
The present disclosure relates to polypeptide modulators of complement activity, including cyclic polypeptide modulators.
Alonso Ricardo, Steven James DeMarco, Sylvia Tobe, Michelle Denise Hoarty, Robert Paul Hammer, Douglas A. Treco, Kathleen Seyb, Vaishnavi Rajagopal, Guo-Qing Tang, Douangsone D. Vadysirisack, Ramin Farzaneh-Far
Filed: 12 Aug 21
Utility
Modulators of complement activity
25 Jul 23
The present invention provides polypeptide modulators of complement activity, including cyclic polypeptide modulators.
Michelle Denise Hoarty, Ketki Ashok Dhamnaskar, Daniel Elbaum, Kristopher Josephson, Kelley Cronin Larson, Zhong Ma, Nathan Ezekiel Nims, Alonso Ricardo, Kathleen Seyb, Guo-Qing Tang, Douglas A. Treco, Zhaolin Wang, Ping Ye, Hong Zheng, Sarah Jacqueline Perlmutter
Filed: 7 Jan 21
Utility
Cyclic Polypeptides for PCSK9 Inhibition
20 Apr 23
Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds.
Alonso Ricardo, Thomas Joseph Tucker, Nicolas Cedric Boyer, Ketki Ashok Dhamnaskar, Zhong Ma, Angela Dawn Kerekes, Chengwei Wu, Sookhee Nicole Ha, Hyewon Youm, Elisabetta Bianchi, Danila Branca, Raffaele Ingenito, Willy Costantini, Aurash Shahripour, Yusheng Xiong
Filed: 29 Aug 22
Utility
Complement Modulators and Related Methods
13 Apr 23
The present disclosure presents compounds and compositions that interact with complement components.
Willmen Wing-Menn Youngsaye, Bolin Geng, Michael R. Hale, Vincent P. Galullo, Jayashree G. Tikhe, Timothy Ryan Siegert, Alonso Ricardo, Derek M. LaPlaca, Douangsone D. Vadysirisack, Guo-Qing Tang, Kathleen Seyb, Michelle Denise Hoarty, Jonathan C. Blain, Joseph R. Stringer, Yongjin Gong, Claudio Sturino, Shawn Gallagher-Duval, Colin Diner, Burcin Akgun, Qing Cao, Douglas A. Treco, Vaishnavi Rajagopal, Ketki Ashok Dhamnaskar, Zhong Ma, Susan Ashwell, Jennifer Davoren, Xiaorong Liu, Camil Sayegh, Wenqing Xu, Alex Lemire, Audrey Belouin, Alexandria Jeanneret, Andrew Hildering, Barbara Bertani, Fabrizio MIcheli, Bemardo Pezzati, Alfonso Pozzan
Filed: 27 Mar 20
Utility
Modulation of complement activity
27 Dec 22
The present invention provides modulators of complement activity.
Michelle Denise Hoarty, Ketki Ashok Dhamnaskar, Daniel Elbaum, Kristopher Josephson, Kelley Cronin Larson, Zhong Ma, Nathan Ezekiel Nims, Alonso Ricardo, Kathleen Seyb, Guo-Qing Tang, Douglas A. Treco, Zhaolin Wang, Ping Ye, Hong Zheng, Sarah Jacqueline Perlmutter, Robert Paul Hammer
Filed: 19 Apr 22
Utility
Cyclic polypeptides for PCSK9 inhibition
20 Dec 22
Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds.
Alonso Ricardo, Thomas Joseph Tucker, Nicolas Cedric Boyer, Joseph R. Stringer, Derek M. LaPlaca, Angela Dawn Kerekes, Chengwei Wu, Sookhee Nicole Ha, Hyewon Youm, Mark W. Embrey, Elisabetta Bianchi, Danila Branca, Raffaele Ingenito, Willy Costantini, Alessia Santoprete, Roberto Costante, Immacolata Conte, Stefania Colarusso, Eric J. Gilbert, Aurash Shahripour, Yusheng Xiong
Filed: 20 Jun 19
Utility
Neurological Disease Treatment with Complement Inhibitors
24 Nov 22
The present disclosure provides methods of treating inflammatory indications with complement inhibitor compounds and compositions.
Simon J. READ, Alonso RICARDO, Camil SAYEGH, Xiangyang XU, Yalan TANG, Guo-Qing TANG
Filed: 11 Sep 20
Utility
Cyclic polypeptides for PCSK9 inhibition
22 Nov 22
Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds.
Alonso Ricardo, Thomas Joseph Tucker, Nicolas Cedric Boyer, Ketki Ashok Dhamnaskar, Zhong Ma, Angela Dawn Kerekes, Chengwei Wu, Sookhee Nicole Ha, Hyewon Youm, Elisabetta Bianchi, Danila Branca, Raffaele Ingenito, Willy Costantini, Aurash Shahripour, Yusheng Xiong
Filed: 20 Jun 19
Utility
Cyclic Polypeptides for PCSK9 Inhibition
3 Nov 22
Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds.
Alonso Ricardo, Nicolas Cedric Boyer, Joseph R. Stringer, Derek M. LaPlaca, Ketki Ashok Dhamnaskar, Zhong Ma, Jonathan C. Blain, Rohit Vyasamneni
Filed: 20 Jun 19
Utility
Inflammatory Disease Treatment with Complement Inhibitors
18 Aug 22
The present disclosure provides methods of treating inflammatory indications with complement inhibitor compounds and compositions.
Petra DUDA, Ramin FARZANEH-FAR, Alonso RICARDO, Camil SAYEGH, Nanqun ZHU, Douangsone D. VADYSIRISACK, Olivier BOYER, Laurent DROUOT
Filed: 4 Jun 20
Utility
Modulators of Complement Activity
28 Jul 22
The present disclosure relates to polypeptide modulators of complement activity, including cyclic polypeptide modulators.
Alonso Ricardo, Steven James DeMarco, Sylvia Tobe, Michelle Denise Hoarty, Robert Paul Hammer, Douglas A. Treco, Kathleen Seyb, Vaishnavi Rajagopal, Guo-Qing Tang, Douangsone D. Vadysirisack, Ramin Farzaneh-Far
Filed: 12 Aug 21
Utility
Modulators of Complement Activity
26 May 22
The present disclosure provides compounds, compositions, and methods for modulating complement activity.
Zhong Ma, Nanqun Zhu, Evan Thackaberry, Ramin Farzaneh-Far, Alonso Ricardo
Filed: 6 Mar 20
Utility
Neurological Disease Treatment with Zilucoplan
5 May 22
Embodiments of the present disclosure include methods of treating myasthenia gravis, including generalized myasthenia gravis, by providing C5 complement inhibitors.
Petra Duda, Ramin Farzaneh-Far, Zhong Ma, Nanqun Zhu, Evan Thackaberry, Alonso Ricardo
Filed: 22 Oct 19
Utility
Cyclic Polypeptides for PCSK9 Inhibition
24 Mar 22
Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds.
Alonso Ricardo, Nicolas Cedric Boyer, Joseph R. Stringer, Derek M. LaPlaca, Kelli Jette, Yili Sun
Filed: 20 Jun 19
Utility
Modulators of complement activity
21 Sep 21
The present disclosure relates to polypeptide modulators of complement activity, including cyclic polypeptide modulators.
Alonso Ricardo, Steven James DeMarco, Sylvia Tobe, Michelle Denise Hoarty, Robert Paul Hammer, Douglas A. Treco, Kathleen Seyb, Vaishnavi Rajagopal, Guo-Qing Tang, Douangsone D. Vadysirisack, Ramin Farzaneh-Far
Filed: 7 Dec 17
Utility
Modulators of Complement Activity
16 Sep 21
The present invention provides polypeptide modulators of complement activity, including cyclic polypeptide modulators.
Michelle Denise Hoarty, Ketki Ashok Dhamnaskar, Daniel Elbaum, Kristopher Josephson, Kelley Cronin Larson, Zhong Ma, Nathan Ezekiel Nims, Alonso Ricardo, Kathleen Seyb, Guo-Qing Tang, Douglas A. Treco, Zhaolin Wang, Ping Ye, Hong Zheng, Sarah Jacqueline Perlmutter
Filed: 7 Jan 21